FemAid, a medical device company focused on women's health, has completed the prototyping phase and filed a patent application for its non-surgical, non-drug incontinence device. The device utilizes a check valve placed in the urethra that can be adjusted to meet individual needs. It stops urine flow until activated by pressure on the bladder and is made with body-friendly Teflon material for maximum comfort. Female urinary incontinence affects over one billion women worldwide and FemAid aims to provide an alternative solution to invasive or drug-based treatments.
The completion of the prototyping phase is a significant milestone for FemAid as it moves towards bringing this innovative device to market. The company is actively seeking investors to accelerate development and navigate FDA certification processes while maintaining safety and efficacy standards. For more information about FemAid and their groundbreaking device, please contact CEO Richard Langson.
Female urinary incontinence is a common problem that affects many women around the world. While there are surgical or drug-based treatments available, they may not be suitable for everyone. FemAid, a medical device company focused on women's health, has completed the prototyping